National Health Insurance Fund

ZimVie Announces Expanded Reimbursement and Exemplary Clinical Rating for Mobi-C®

Retrieved on: 
Monday, April 3, 2023
Systematic review, 10A, Surgeon, Health Insurance Fund, Physician, National Health Insurance Fund, Republic, Motion, Patient, JORF, Biomedical text mining, United Kingdom, National Institute for Health and Care Excellence, FDA, WHO model list of essential in vitro diagnostics, LPP, News, NICE, Medical device, Health

In addition, the clinical data for Mobi-C was awarded the highest quality rating of 10A* by the Orthopaedic Data Evaluation Panel in the United Kingdom.

Key Points: 
  • In addition, the clinical data for Mobi-C was awarded the highest quality rating of 10A* by the Orthopaedic Data Evaluation Panel in the United Kingdom.
  • “This reimbursement of the Mobi-C prosthesis is really excellent news.
  • ODEP provides the objective, systematic review and rating of the strength of evidence supporting the performance of medical devices.
  • “We applaud the French reimbursement decision for Mobi-C and welcome the exemplary 10A* rating from ODEP,” said Rebecca Whitney, Global President of ZimVie Spine.

Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic

Retrieved on: 
Tuesday, November 1, 2022
Weight gain, Severe cognitive impairment, Intraocular pressure, Alimera Sciences, SEC, Organization, GLOBE, Financial condition report, Central, National Health Insurance Fund, Swelling, Medis, Private Securities Litigation Reform Act, CEE, Achievement, Uveitis, Adult, DME, Result, State Institute for Drug Control, Patient, Recurrence, Osteoporosis, Infection, Diabetic retinopathy, Sleep, Mutual, Czech Republic, Cancer, Hypertension, Risk, Physician, Disease, Eye, Injection, Fluocinolone acetonide, Analysis, Annual report, Acne, Pharmaceutical industry, Medical device, Trosia

ATLANTA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis, through its distribution partner, Medis Pharmaceutical Company. After the National Health Insurance Fund (NHIF) agreed to the unmet need and budget impact, the State Institute for Drug Control (SUKL) in the Czech Republic issued a positive decision that ILUVIEN is reimbursed for the prevention of the relapse in adult patients with recurrent non-infectious uveitis affecting the posterior segment of the eye.

Key Points: 
  • We are pleased to gain this reimbursement in the Czech Republic and thankful to our partner Medis for this achievement and for their upcoming launch, said Rick Eiswirth, President and Chief Executive Officer of Alimera.
  • The Companys primary product ILUVIEN is a sustained release intravitreal implant injected into the back of the eye.
  • The non-infectious uveitis affecting the posterior segment indication for ILUVIEN was launched in Germany and the U.K. in late 2019, Belgium in 2021 and Ireland, Spain, and Italy in 2022.
  • Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf.

Health2Sync and AstraZeneca Taiwan to Kick off Digital Patient Management Programs for Chronic Kidney Diseases

Retrieved on: 
Wednesday, July 13, 2022
Healthline, Conditional sentence, CKD, Diabetes, National health insurance, Risk, Patient, CEO, Physician, Diagnosis, AstraZeneca, MOU, Chronic kidney disease, National Health Insurance Fund, HIV disease progression rates, Single-frequency network, Blood, Partnership, Platform, Pharmaceutical industry, Medical device

TAIPEI, July 13, 2022 /PRNewswire/ -- Health2Sync, Asia's leading digital chronic disease management platform, announced today that it is signing a Memorandum of Understanding (MOU) with AstraZeneca Taiwan to provide its first digital solution for chronic kidney disease (CKD) patients in Taiwan.

Key Points: 
  • TAIPEI, July 13, 2022 /PRNewswire/ -- Health2Sync, Asia's leading digital chronic disease management platform, announced today that it is signing a Memorandum of Understanding (MOU) with AstraZeneca Taiwan to provide its first digital solution for chronic kidney disease (CKD) patients in Taiwan.
  • The partnership targets to reach an early diagnosis and optimize the quality of everyday chronic kidney disease care through the smart detection feature on the Health2Sync patient management platform, which is currently used by over 400 medical institutions worldwide.
  • Through the new partnership with AstraZeneca, Health2Sync is demonstrating its plans to provide digital touchpoints for the management of other disease areas such as CKD and cardiovascular.
  • Established in 2013, Health2Sync aims to provide personalized and scalable digital solutions for chronic disease patients.